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the lesions. The two systems did not differ statistically for 
correlation with the final histology (S1 k = 0.94 ± 0.06; 
S2 k = 0.92 ± 0.08) and underestimation of B3 lesions or 
in situ (S1 4.5 %; S2 4.3 %). Sensitivity, specificity, PPV, 
NPV, diagnostic accuracy of S1 and S2 were also not sta-
tistically different. The systems differed only in sampling 
time (S1 80; S2 63 s), but not in total procedure time.
Conclusions Our study confirms the effectiveness of 
VABB in the assessment of microcalcifications and high-
lights the lack of significant differences between the two 
systems in terms of diagnostic performance.
Keywords Breast cancer · Vacuum-assisted core biopsy · 
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Introduction
It is widely recognised that the development of systems for 
minimally invasive needle biopsy (Tru-Cut needle biopsy 
and vacuum-assisted breast biopsy, VABB) has increased 
the diagnostic accuracy of percutaneous needle biopsies. 
In particular, the introduction of VABB systems into clini-
cal practice has allowed researchers to reduce the amount 
of surgical biopsies performed for diagnostic purposes, so 
reducing the associated costs [1]. The major advantage of 
VABB is the chance to withdraw a number of samples suf-
ficient for an accurate diagnosis with a single insertion of 
the needle and even, in some cases, to completely remove 
the lesion. VABB also removes a greater amount of mate-
rial, thus reducing the likelihood of preoperative underes-
timation, as well as the need to repeat the procedure due to 
the inadequacy of sampled tissue [2]. The VABB systems 
(gauge 7–11) can be used with stereotactic guidance (either 
using upright devices or prone table systems), ultrasound or 
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magnetic resonance. According to the European Guidelines 
[3, 4] they can be considered the method of choice for sam-
pling nonpalpable lesions, such as:
–– groups of microcalcifications with indistinct morphol-
ogy, for which the removal of a greater volume of tissue 
for accurate histological evaluation is required;
–– groups of microcalcifications distributed in small clus-
ters, difficult to sample (<5 mm);
–– groups of microcalcifications suspected of malignancy, 
to increase the chances of detecting invasive foci;
–– discordant results (B1, B3, or B4) after needle biopsy 
using 14G conventional core biopsy;
–– architectural distortion;
–– diagnostic excision of papillary lesions after core 
biopsy.
The effectiveness and accuracy of a VABB system is 
generally evaluated in the literature by using parameters 
such as the percentages of underestimation of prolifera-
tive risk lesions, classified as B3 (most frequently atypi-
cal ductal hyperplasia (ADH) versus ductal carcinoma in 
situ) and the underestimation of malignant lesions in situ, 
usually ductal carcinoma in situ (DCIS) versus infiltrating 
malignant lesions [5].
There are various VABB systems on the market (Suros®, 
Vacora®, Mammotome®, EnCor®) which have in common 
the use of forced aspiration and the option of using large-
calibre needles (14–7G) [6].
The different systems are divided mainly into open or 
closed, depending on whether the tissue sampling is per-
formed manually or automatically. In this study, we com-
pared two VABB devices, one open with manual sampling 
Mammotome® (Devicor Medical Products, Inc., Cincin-
nati, Ohio, USA) and one closed with automated sampling 
(EnCor®, SenoRx, Aliso Viejo, CA) to evaluate their diag-
nostic performances.
Materials and methods
Study design
Between January 2011 and July 2012, we compared two 
different VABB systems. Over this period, 169 consecutive 
VABB procedures were performed in all cases with the aim 
of evaluating areas of suspicious mammographic micro-
calcifications not associated with other signs (asymmetric 
densities, structural distortions masses or opacities). All the 
areas of microcalcifications were classified BIRADS 4 and 
divided into subcategories 4a, b and c [7]. All procedures 
were performed using a Fischer stereotactic prone table 
(Fischer Medical Technologies, USA) with Mammotome 
probes®, 11G (Mammotome®, Devicor Medical Products, 
Inc., Cincinnati, Ohio, USA) or EnCor® 10G (EnCor®, 
SenoRx, Aliso Viejo, CA).
The patients were divided into two groups according to 
the device used for each procedure. The choice of which 
needle biopsy system to use was made randomly. In the 
period under consideration, we performed a weekly ses-
sion by VABB needle biopsy system, alternating between 
the two sampling systems at our disposal. All patients had 
previously undergone digital mammography in two stand-
ard projections (cranio-caudal and medio-lateral oblique). 
The digital mammographic devices used were Lorad Sele-
nia and Selenia Dimensions Lorad (Hologic, Bedford, MA, 
USA). In all cases, a complementary ultrasound examina-
tion was performed.
All VABB procedures were performed after obtaining 
the informed consent of the patient.
Biopsy technique
A stereotactic digital Mammotest Fischer prone table was 
used (Fischer Medical Technologies, USA) connected to a 
computer equipped with Mammovision software.
The initial localisation phase is the same for both proce-
dures. Evaluation of the lesion is made with a radiographic 
scout view at 0° and then subsequently two stereotactic 
projections at +15° and −15° are run.
After selecting the type of biopsy needle system to use 
and the relative calibre of needle, the software follows 
stereotactic principles and transmits the numerical values 
that govern the placement and depth of the needle into the 
lesion to the device command unit, where the probe is to be 
installed.
Local anaesthesia is performed with 1 % lidocaine 
(10 mL), followed by two stereotactic projections at +15° 
and −15° to confirm the correct target.
If, after the injection, the target is not correct, it is re-
centred. The next step is the insertion of the needle. In the 
case of the Mammotome® probe it is necessary to make 
a 4–5-mm-long incision with a scalpel. This procedure is 
not necessary with the EnCor® probe (10 gauge G, with 
a standard chamber biopsy opening of 19 mm), equipped 
with a tri-concave tip.
Subsequently two stereotactic pre-fire projections are 
performed to verify the correct distance between the nee-
dle tip and the lesion, and then two post-fire projections to 
check that the target is at the centre of the biopsy needle 
chamber. The sampling phase comes next, during which the 
breast tissue is excised by a rotating blade, in conjunction 
with forced aspiration, and placed in the sample chamber.
With the Mammotome® probe the position of the camera 
is controlled manually and the samples must be removed 
individually by the operator (open system) and placed on 
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an appropriate support such as absorbent paper and ade-
quately irrigated with physiological saline solution.
The EnCor® is an automatic sampling system with pre-
programmed probe, the number and location of the sam-
ples are all that is needed before starting. An option can be 
selected that allows you to reduce the opening of the biopsy 
needle chamber, which is useful for superficial lesions. This 
is not available with the Mammotome® system that we used 
(our model of Original Mammotome® ST, calibre 11G, came 
with the opening of the biopsy needle chamber at 20 mm), 
which provides the alternative of a small reducer to place 
above the biopsy needle chamber before the procedure. The 
needle picks up the EnCor® frustules that are expelled into a 
separate chamber, from which they are extracted at the end of 
the sampling (closed system). After six withdrawals, the col-
lected material is removed and replaced. With this system it is 
not possible to determine the exact order in which the various 
cores were collected. The system is supplied with a cleaning 
function to cleanse the chamber with saline solution.
For both procedures, when used for the characterisation of 
microcalcifications, mammograms are performed with direct 
radiological magnification of the cores to assess the presence 
of microcalcifications in the tissue samples. All cores are 
then placed in a container with 10 % formalin, the samples 
containing microcalcifications being marked with Indian ink.
At the end of both procedures it is possible to position a 
marker consisting of a nonmagnetic metal clip that identi-
fies the site of the needle biopsy.
At about 2 weeks after the procedure, all patients 
underwent mammographic evaluation of the correct posi-
tioning of the clip and the possible presence of residual 
microcalcifications.
Interpretation of results
According to the European Guidelines, the microhistologi-
cal examinations of the samples obtained by VABB were 
classified into five categories: B1 = normal, B2 = benign, 
B3 = lesion of uncertain significance, B4 = suspected 
malignancy, B5 = malignant [8].
The lesions classified as benign (B2) were monitored 
with follow-up mammograms at 6–12 months.
For all lesions classified as B1–B3, diagnostic surgical 
biopsy after multidisciplinary consultation was advised. 
The lesions classified as B4 or B5 underwent surgical 
excision.
Definitive histological examination was considered the 
gold standard for the comparison of results and the diag-
nostic performance of the VABB probes. In cases of B4 or 
B5 lesions completely removed by VABB and no longer 
histologically present we proceeded to the pathological 
evaluation of the samples collected by needle biopsy for 
appropriate cancer treatment. For both systems we evalu-
ated the sensitivity, specificity, positive predictive value 
(PPV), negative predictive value (NPV), diagnostic accu-
racy, sampling time and the number of cores taken.
Statistical analysis
The continuous variables, expressed as averages with 
standard deviation, were analysed with Student’s t test and 
the nonparametric Mann–Whitney test. The category varia-
bles were instead compared by contingency tables analysed 
with the Chi square test and with 2 × 2 tables using the 
Yates or Fischer correction. The concordance between the 
results of the microhistological examination and the defini-
tive histological examination was calculated using Cohen’s 
coefficient.
Results
The radiological characteristics of the lesions in the two 
groups of patients divided according to the device used 
for the VABB procedure (Mammotome® or EnCor®) 
were comparable (Table 1) with no statistically significant 
differences.
The average time taken for the removal of 6 cores was 
respectively 63 s with probe EnCor® vs. 80 s with Mam-
motome® probe, with a statistically significant difference 
(p < 0.01). The overall duration of the procedures was not 
Table 1  Characteristics of the two study groups
EnCor Mammotome p value Overall procedures
Number of procedures 82 87 169
Patient age (mean ± standard deviation) 52.72 ± 9.52 53.88 ± 9.74 0.46 53.34 ± 9.63
Lesion size (mm) (mean ± standard deviation) 8.24 ± 4.71 8.84 ± 5.86 0.44 8.58 ± 5.38
Microcalcifications as only mammographic sign 82 87 0.98 169
Lesion BIRADS classification
 R4a 90.24 % (74/82) 90.80 % (79/87) 0.58 90.53 % (153/169)
 R4b 9.76 % (8/82) 9.19 % (8/87) 9.47 % (16/169)
 R4c 0 0 – 0
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statistically significantly different between the two systems. 
On average 9.73 (range 6–18) cores were collected with the 
EnCor® system and 9.68 (range 6–18) cores with the Mam-
motome® system (Table 2), with no statistically significant 
differences between the two systems.
Also with regard to the results of the microhistological 
VABB samples obtained with the two systems, there were 
no statistically significant differences, as summarised in 
Table 3 (Figs. 1, 2, 3, 4).
With the Mammotome probe, in no case did the sam-
ple prove inconclusive. With the probe EnCor one case 
(1.22 %) was classified B1 after the microhistology 
examination (Table 3). In this case, the procedure was 
interrupted due to major bleeding. In the 6 cores taken 
no microcalcifications were present. After surgical exci-
sion biopsy, the lesion proved to be benign on histological 
examination.
The only complication observed was the formation of 
haematoma at the site of collection. In particular, during 
the check performed 2 weeks after the procedure, we found 
four blood collections after biopsy with the EnCor probe 
and three with the Mammotome probe (for both systems, 
the collections had ultrasound dimensions between 1 and 
2 cm).
The lesions classified as B2, with follow-up mammogra-
phy performed for at least 1 year, were negative in all cases.
All VABB with microhistological results classified as B3 
received surgical biopsy after multidisciplinary discussion 
in the course of diagnostic-therapeutic consultations at the 
Breast Unit. All VABB with microhistology results of B5 
(no case was classified B4) were sent to surgery.
In four cases of malignant lesions in situ complete exci-
sion was achieved of the area of microcalcifications with 
the Mammotome® probe: at final histology, in two cases 
(average size 10.5 mm) there were no malignant cells 
in the surgical specimen, in the other two cases (aver-
age size 11 mm) a complex sclerosing lesion with foci of 
Table 2  Comparison between the two different devices considering procedure time and sampling
EnCor (N = 82) Mammotome (N = 87) p value
Number of samples taken (mean ± standard deviation) 9.73 ± 2.12 9.68 ± 2.25 0.88
Time to sample 6 specimens (sec) (mean ± standard deviation) 63 ± 9.52 80 ± 12.21 <0.01
Total duration of the procedure (min) (mean ± standard deviation) 54 ± 12 55 ± 15 0.55
Table 3  Results of the microhistological examination on the vac-
uum-assisted breast biopsy specimens
EnCor Mammotome
B1 1.22 % (1/82) 0 % (0/87)
B2 69.51 % (57/82) 62.07 % (54/87)
B3 14.63 % (12/82) 17.24 % (15/87)
B4 0.00 % (0/82) 0.00 % (0/87)
B5 14.63 % (12/82) 20.69 % (18/87)
 B5a 9.76 % (8/82) 20.69 % (18/87)
 B5b 2.44 % (2/82) 0.00 % (0/87)
 B5c 2.44 % (2/82) 0.00 % (0/87)
Fig. 1  Magnification views of a 5-mm cluster of heterogeneous and 
polymorphous microcalcifications classified as BIRADS 4b, which 
underwent Mammotome® vacuum-assisted biopsy
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atypical ductal hyperplasia (DIN1B) and flat epithelial 
atypia (DIN1A) were present. With the EnCor® probe two 
areas of microcalcifications were totally excised: one area 
(diameter 7 mm) was classified as B3 at microhistological 
examination and on final pathology no residual lesion was 
found; similarly, the other totally excised area of microc-
alcifications (diameter 10 mm) was classified as B5a at 
microhistological examination and on final histology no 
residual in situ or invasive carcinoma was found (Tables 4, 
5). The correlation between the microhistology outcome 
and the definitive histology expressed by Cohen’s coef-
ficient was equivalent for both probes: 0.92 ± 0.08 (95 % 
CI 0.75–1) for the EnCor system (Table 6) and 0.94 ± 0.06 
(95 % CI 0.82–1) for the Mammotome system (Table 7), 
with no statistically significant differences between the 
two.
With regard to the underestimation of the lesions of 
uncertain biological potential (B3) or in situ (B5a) for both 
systems the shortcoming was broadly equivalent: using 
the EnCor® probe in 1/22 cases (4.5 %) and in 1/23 cases 
(4.3 %) with Mammotome®.
With EnCor, no B3 lesion was underestimated, but one 
case diagnosed as B5a (DCIS with papillary aspects) proved 
to be an infiltrating tubular carcinoma with papillomas and 
columnar cell modifications, at final histological examination.
With Mammotome, no B5a was later identified as an 
infiltrating lesion but one case diagnosed as B3 (radial scar) 
at final histological examination proved to be a low-grade 
DCIS (DIN1C) arising in radial scar.
Regarding the diagnostic performance of the two probes 
(Table 8) the values obtained in terms of sensitivity, speci-
ficity, PPV, NPV and accuracy were compared using the 
Chi square test with Yates correction and were not statisti-
cally different.
Discussion
In this series, the Mammotome® and EnCor® VABB 
systems achieved equivalent results with regard to their 
Fig. 2  Magnification view of breast tissue specimens removed by 
Mammotome® in the same case of Fig. 1: the microhistological find-
ing was B5b (infiltrating lobular carcinoma), confirmed at the final 
histological examination
Fig. 3  Magnification views of a 7-mm cluster of microcalcifications 
with predominantly granular morphology and ductal distribution, 
classified as BIRADS 4b, which underwent EnCor® vacuum-assisted 
biopsy
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performance in terms of sensitivity, specificity and diag-
nostic accuracy. The effectiveness of the Mammotome® 
system has been demonstrated in a large number of stud-
ies in the literature [1, 5, 9], while for the EnCor® sys-
tem, more recently introduced in interventional breast 
imaging, experience is more limited [10].
Our data support the validity of the EnCor® system for 
the assessment of areas of suspicious microcalcifications, 
as comparable to the Mammotome® system.
The two systems used in this study differ in the size of 
the probe needle, with the EnCor® using the larger (10G) 
needle compared to the Mammotome® (11G). This differ-
ence in size, a single value in the Gauge scale, did not lead 
to superior performance as also observed by Lourenco et al. 
[11]. Significantly better performances were observed when 
greater calibre differences were considered, as in the study by 
Venkataraman et al. [12], who compared 8G vs. 11G needles.
Both systems allow complete excision of microcalcifi-
cations in some cases, although the objective of VABB is 
exclusively diagnostic. The complete excision of microcal-
cifications is not to be considered an advantage compared 
to other techniques for percutaneous VABB needle biopsies 
since the goal is not therapeutic [13]. In this regard, a reduc-
tion of the underestimation of malignancy with an increase 
of the diagnostic accuracy of the procedure was observed in 
the case of a complete excision of the lesions [14].
Both VABB system results are highly sensitive and 
specific in the assessment of suspicious microcalcifica-
tions with values similar to those obtained in the study of 
Zuiani et al. [15] (sensitivity 98.7 %, specificity 83.7 %). 
Our study differs as regard to the prediction of positivity 
which it assesses as lower. This difference was caused in 
our series by the fact that most of the lesions classified 
as B3 were not malignant upon surgical verification. This 
could be mostly due to the type of mammographic altera-
tions we selected to undergo to VABB procedures. Most 
of the cases had been classified as BIRADS 4a, in a few 
cases 4b and in no case 4c. The subdivision of the class 
BIRADS 4 into subcategories, introduced in the fourth 
edition [7], improves the accuracy in the classification of 
Fig. 4  Magnification view of breast tissue specimens removed by 
EnCor® in the same case of Fig. 3: the microhistological finding was 
ductal cribriform carcinoma in situ (B5a); at the final histological 
examination there was columnar hyperplasia without atypia and no 
residual carcinoma
Table 4  Vacuum-assisted biopsy-proven B3 lesions: comparison 
with final histological examination
DIN 1A flat epithelial atypia, DIN 1B atypical ductal hyperplasia, 
DIN 1C low-grade ductal carcinoma in situ (grade 1), NA not appli-
cable
a
  Normal breast parenchyma
b
  Underestimation of radial scar on VAAB
Final histological 
examination
EnCor (N = 12) Mammotome 
(N = 15)
p value
DIN1A 4 7 0.76
DIN1B 6 – NA
DIN1C 1b NA
DIN1A + DIN1B 1 1 NA
Radial scar – 4 NA
Sclerosing papillomas – 2 NA
Complete excision 1a – NA
Table 5  Vacuum-assisted biopsy-proven B5 lesions: comparison 
with final histological examination
DIN 1C grade 1 ductal carcinoma in situ, DIN 2 grade 2 ductal car-
cinoma in situ, DIN 3 grade 3 ductal carcinoma in situ, IDC invasive 
ductal carcinoma, ILC invasive lobular carcinoma, LIN2 lobular car-
cinoma in situ, classic type, NA not applicable
a
  Case of VABB underestimation (biopsy-proven ductal carcinoma 
in situ)
b
  Normal breast parenchyma with no residual ductal carcinoma in 
situ
c
  1 Case DIN1A (flat epithelial atypia), 1 case DIN1B (atypical 
ductal hyperplasia), 2 cases normal breast parenchyma without resid-
ual carcinoma
Final histological 
examination
EnCor N = 12 Mammotome N = 18 p value
DIN1C 1 2 0.71
DIN2 3 4 0.79
DIN3 4 8 0.82
IDC + DIN3 1 – NA
Invasive tubular carci-
noma + DIN1B
1a – NA
ILC + LIN2 1 – NA
Complete excision 1b 4c NA
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the likelihood of malignancy [16], but with regard to less 
suspicious lesions, such as those classifiable as 4a, mam-
mographic abnormalities classified as BIRADS 3 could be 
included in this group due to their greater variability and 
lesser concordance among observers as shown in previous 
studies [17, 18]. Consequently, the malignancy associated 
with lesions classified as B3 may be more variable and 
tends to be lower. Taking into account these variables, the 
technical characteristics of the VABB system used do not 
seem to have the potential to increase the PPV.
The strength of the VABB systems lies, however, in their 
high predictive value for the absence of malignancy (VPN). 
In this study and in our previous wider experience [1] in no 
case of VABB microhistological findings classified as benign 
did we later find the onset of a malignant lesion in the VABB 
sampling site, in agreement with other studies [8, 13, 19, 20].
A second advantage of using VABB systems compared 
to core biopsy with conventional semiautomatic systems 
is the reduction of the underestimation of lesions of uncer-
tain biological potential or malignant in situ lesions. Both 
VABB systems used give very accurate results in our series 
Table 6  Correlation between the microhistological results by EnCor system and the final histological examination
EnCor B1* B2* B3* B5a* B5b* B5c*
Non-operated patients 0 57 0 0 0 0
Histological examination: benign 1 0 12 0 0 0
Histological examination: DCIS 0 0 0 7 0 2
Histological examination: IC 0 0 0 1 2 0
Total 1 57 12 8 2 2
The grey cells report the data used to calculate the Cohen’s kappa coefficient of agreement [k = 0.92 ± 0.08; CI 95 % (confidence interval) 
0.75–1]
DCIS ductal carcinoma in situ, IC invasive carcinoma
A
  According to the European Guidelines [8]
Table 7  Correlation between the microhistological results by Mammotome system and the final histological examination
MAMMOTOME B1 B2 B3 B5a B5b B5c
Non-operated patients 0 54 0 0 0 0
Histological examination: benign 0 0 14 0 0 0
Histological examination: DCIS 0 0 1 18 0 0
Histological examination: IC 0 0 0 0 0 0
Total 0 54 15 18 0 0
The grey cells report the data used to calculate the Cohen’s kappa coefficient of agreement [k = 0.94 ± 0.06; CI 95 % (confidence interval) 
0.82–1]
DCIS ductal carcinoma in situ cancer, IC invasive carcinoma
Table 8  Comparison of the diagnostic performance of the two sys-
tems, considering B3 lesions as a positive prediction of cancer
SN sensitivity, SP specificity, PPV positive predictive value, NPV 
negative predictive value, AC diagnostic accuracy, CI confidence 
interval, NA not applicable
EnCor Mammotome p value
% Lower–Upper 
95 % CIs
% Lower–Upper 
95 % CIs
SN 100 (75.75–100) 100 (83.18–100) NA
SP 82.86 (72.38–89.91) 79.41 (68.36–87.32) 0.76
PPV 50 (31.43–68.57) 57.58 (40.81–72.76) 0.77
NPV 100 (93.79–100) 100 (93.36–100) NA
AC 85.37 (76.14–91.43) 83.91 (74.78–90.17) 0.96
376 Radiol med (2015) 120:369–376
1 3
and the underestimation of these types of lesions was infe-
rior to other studies with respect to which it is probably not 
comparable due to the small sample size. As regards the 
processing time, the use of a closed system with automated 
VABB sampling compared to an open one with manual 
sampling resulted in a significant reduction only of the 
time taken to sample the cores (calculated on an average 
of at least 6 cores). The overall duration of the procedures 
(positioning of the patient, pre- and post-fire checks, etc.) 
did not reveal statistically significant variations (Table 2). 
Finally, both systems are highly effective in terms of tech-
nical success of the procedure, of almost 100 %. A failure 
occurred only in one case with the EnCor® probe. How-
ever, this finding cannot be attributed to the system used, 
since failure rates between 0 and 5 % with Mammotome® 
system in previous studies have been described [21–23].
Conclusions
Our study highlights the lack of statistically significant 
differences between the EnCor® system and the Mam-
motome® system for the variables we considered; for this 
reason, even considering the relatively modest number 
of patients, the EnCor® system can be considered by no 
means inferior when compared with the Mammotome® 
procedures under stereotactic guidance.
Our data also confirm the effectiveness of the VABB 
procedures in the assessment of suspicious microcalcifica-
tions as a single mammographic sign for the purposes of 
proper planning of surgical treatment.
Conflict of interest The authors declare no conflict of interest.
References
 1. Luparia A, Durando M, Campanino P et al (2011) Efficacy and 
cost-effectiveness of stereotactic vacuum-assisted core biopsy 
of nonpalpable breast lesions: analysis of 602 biopsies per-
formed over 5 years. Radiol Med 116:477–488. doi:10.1007/
s11547-011-0625-x
 2. Park HL, Kim LS (2011) The current role of vacuum assisted 
breast biopsy system in breast disease. J Breast Cancer 14:1–7. 
doi:10.4048/jbc.2011.14.1.1
 3. Perry N, Broeders M, De Wolf C et al (2008) European guide-
lines for quality assurance in breast cancer screening and diagno-
sis. Fourth edition––summary document. Ann Oncol 19:614–622
 4. Wilson R, Liston J (2010) Clinical Guidelines for Breast Cancer 
Screening Assessment, 3rd edn. NHSBSP Publication No 49. 
Available from: http://www.cancerscreening.nhs.uk/breastscreen/
publications/nhsbsp49.html. Accessed 1 Mar 2014
 5. Bernardi D, Borsato G, Pellegrini M et al (2012) On the diagnos-
tic accuracy of stereotactic vacuum-assisted biopsy of nonpalpa-
ble breast abnormalities. Results in a consecutive series of 769 
procedures performed at the Trento Department of Breast Diag-
nosis. Tumori 98:113–118. doi:10.1700/1053.11509
 6. Wallis M, Tardivon A, Helbich T, Schreer I (2007) Guidelines 
from the European Society of Breast Imaging for diagnostic 
interventional breast procedures. Eur Radiol 17:581–588
 7. American College of Radiology (2003) Guidance chapter. Breast 
Imaging Reporting and Data System Atlas (BI-RADS® Atlas). 
Reston, Va: © American College of Radiology, pp 253–259
 8. Ellis IO, Humphreys S, Michell M, UK National Coordinating 
Committee for Breast Screening Pathology, European Commis-
sion Working Group on Breast Screening Pathology et al (2004) 
Best practice no 179. Guidelines for breast needle core biopsy 
handling and reporting in breast screening assessment. J Clin 
Pathol 57:897–902
 9. Dhillon MS, Bradley SA, England DW (2006) Mammotome 
biopsy: impact on preoperative diagnosis rate. Clin Radiol 
61:276–281
 10. Wang ZL, Liu G, Huang Y et al (2012) Percutaneous excisional 
biopsy of clinically benign breast lesions with vacuum-assisted 
system: comparison of three devices. Eur J Radiol 81:725–730. 
doi:10.1016/j.ejrad.2011.01.059
 11. Lourenco AP, Mainiero MB, Lazarus E et al (2007) Stereotactic 
breast biopsy: comparison of histologic underestimation rates 
with 11- and 9-gauge vacuum-assisted breast biopsy. AJR Am J 
Roentgenol 189:W275–W279
 12. Venkataraman S, Dialani V, Gilmore HL, Mehta TS (2012) Ste-
reotactic core biopsy: comparison of 11 gauge with 8 gauge 
vacuum assisted breast biopsy. Eur J Radiol 81:2613–2619. 
doi:10.1016/j.ejrad.2011.10.027
 13. Liberman L, Kaplan JB, Morris EA et al (2002) To excise or to 
sample the mammographic target: what is the goal of stereotactic 
11-gauge vacuum-assisted breast biopsy? AJR Am J Roentgenol 
179:679–683
 14. Penco S, Rizzo S, Bozzini AC et al (2010) Stereotactic vacuum-
assisted breast biopsy is not a therapeutic procedure even when 
all mammographically found calcifications are removed: analysis 
of 4,086 procedures. AJR Am J Roentgenol 195:1255–1260. doi:
10.2214/AJR.10.4208
 15. Zuiani C, Mazzarella F, Londero V et al (2007) Stereotactic 
vacuum-assisted breast biopsy: results, follow-up and correlation 
with radiological suspicion. Radiol Med 112:304–317
 16. Balleyguier C, Ayadi S, Van Nguyen K et al (2007) BIRADS 
classification in mammography. Eur J Radiol 61:192–194
 17. Pijnappel RM, Peeters PH, Hendriks JH, Mali WP (2004) Repro-
ducibility of mammographic classifications for non-palpable sus-
pect lesions with microcalcifications. Br J Radiol 77:312–314
 18. Cos¸ar ZS, Cetin M, Tepe TK et al (2005) Concordance of mam-
mographic classifications of microcalcifications in breast cancer 
diagnosis. Utility of the breast imaging reporting and data system 
(fourth edition). Clin Imaging 29:389–395
 19. Cangiarella J, Waisman J, Symmans WF et al (2001) Mam-
motome core biopsy for mammary microcalcification: analysis of 
160 biopsies from 142 women with surgical and radiologic fol-
low up. Cancer 91:173–177
 20. Chapellier C, Balu-Maestro C, Amoretti N et al (2006) Vacuum-
assisted breast biopsies. Experience at the Antoine Lacassagne 
Cancer Center (Nice, France). Clin Imaging 30:99–107
 21. Meyer JE, Smith DN, Di Piro PJ et al (1997) Stereotactic breast 
biopsy of clustered microcalcifications with a directional, vac-
uum-assisted device. Radiology 204:575–576
 22. Apesteguía L, Mellado M, Sáenz J et al (2002) Vacuum-assisted 
breast biopsy on digital stereotaxic table of nonpalpable lesions 
non-recognisable by ultrasonography. Eur Radiol 12:638–645
 23. Tonegutti M, Girardi V (2008) Stereotactic vacuum-assisted 
breast biopsy in 268 nonpalpable lesions. Radiol Med 113:65–75. 
doi:10.1007/s11547-008-0226-0
